Review PET/CT & SPECT/CT in Theranostics. The presentation should take less than 20 minutes. The audience will primarily be medical physicists specializing in therapeutic medical physics and medical physics residents, so a brief background on each of the imaging modality will be beneficial. List clinical theranostic agents/pairs of diagnostic and therapeutic agents, including I-131 and modern radioligands like Lutathera and Pluvicto, and Ac-225. Also include clinical images of the most common agents. Compare SPECT and PET image quality for at least one agent that can be imaged with both modalities. Introduce quantitative imaging for purposes of dosimetry, but leave out details of dosimetry since another speaker will present those. Do point out how imaging and dosimetry can impact patient care through monitoring distribution and uptake of agents, as well as response to treatment. Mention how scan parameters can impact dosimetryLeave a slide to add our data evaluating the quantitative accuracy of the GE StarGuide when I get details from a collaborator.
Review PET/CT & SPECT/CT in Theranostics. The presentation should take less than 20 minutes. The audience will primarily be medical physicists specializing in therapeutic medical physics and medical physics residents, so a brief background on each of the imaging modality will be beneficial. List clinical theranostic agents/pairs of diagnostic and therapeutic agents, including I-131 and modern radioligands like Lutathera and Pluvicto, and Ac-225. Also include clinical images of the most common agents. Compare SPECT and PET image quality for at least one agent that can be imaged with both modalities. Introduce quantitative imaging for purposes of dosimetry, but leave out details of dosimetry since another speaker will present those. Do point out how imaging and dosimetry can impact patient care through monitoring distribution and uptake of agents, as well as response to treatment. Mention how scan parameters can impact dosimetryLeave a slide to add our data evaluating the quantitative accuracy of the GE StarGuide when I get details from a collaborator.
Created using ChatSlide
Theranostics integrates imaging and treatment, utilizing PET/CT and SPECT/CT to guide therapy and monitor responses. The clinical workflow emphasizes confirming target expression, assessing biodistribution, and using follow-up imaging for evaluation. Key examples include I-123/I-131 for thyroid conditions and 68Ga/177Lu for prostate cancer. Modern radioligands like Pluvicto and Lutathera are emerging, while quantification enhances adaptive care. A clinical image gallery showcases various...